Journal of Medicinal Chemistry
Article
double-blind, randomised, placebo-controlled phase 2 study. Lancet
2016, 387, 679−690.
(35) Briere, D. A.; Ruan, X.; Cheng, C. C.; Siesky, A. M.; Fitch, T.
E.; Dominguez, C.; Sanfeliciano, S. G.; Montero, C.; Suen, C. S.; Xu,
Y.; Coskun, T.; Michael, M. D. Novel small molecule agonist of
TGR5 possesses anti-diabetic effects but causes gallbladder filling in
mice. PLoS One 2015, 10, e0136873.
(36) Piotrowski, D. W.; Futatsugi, K.; Warmus, J. S.; Orr, S. T.;
Freeman-Cook, K. D.; Londregan, A. T.; Wei, L.; Jennings, S. M.;
Herr, M.; Coffey, S. B.; Jiao, W.; Storer, G.; Hepworth, D.; Wang, J.;
Lavergne, S. Y.; Chin, J. E.; Hadcock, J. R.; Brenner, M. B.; Wolford,
A. C.; Janssen, A. M.; Roush, N. S.; Buxton, J.; Hinchey, T.; Kalgutkar,
A. S.; Sharma, R.; Flynn, D. A. Identification of tetrahydropyrido[4,3-
d]pyrimidine amides as a new class of orally bioavailable TGR5
agonists. ACS Med. Chem. Lett. 2013, 4, 63−68.
(37) Phillips, D. P.; Gao, W.; Yang, Y.; Zhang, G.; Lerario, I. K.; Lau,
T. L.; Jiang, J.; Wang, X.; Nguyen, D. G.; Bhat, B. G.; Trotter, C.;
Sullivan, H.; Welzel, G.; Landry, J.; Chen, Y.; Joseph, S. B.; Li, C.;
Gordon, W. P.; Richmond, W.; Johnson, K.; Bretz, A.; Bursulaya, B.;
Pan, S.; McNamara, P.; Seidel, H. M. Discovery of trifluoromethyl-
(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavail-
able TGR5 (GPBAR1) agonists: structure-activity relationships, lead
optimization, and chronic in vivo efficacy. J. Med. Chem. 2014, 57,
3263−3282.
(38) Cao, H.; Chen, Z. X.; Wang, K.; Ning, M. M.; Zou, Q. A.; Feng,
Y.; Ye, Y. L.; Leng, Y.; Shen, J. H. Intestinally-targeted TGR5 agonists
equipped with quaternary ammonium have an improved hypoglyce-
mic effect and reduced gallbladder filling effect. Sci. Rep. 2016, 6,
28676.
(39) Duan, H.; Ning, M.; Zou, Q.; Ye, Y.; Feng, Y.; Zhang, L.; Leng,
Y.; Shen, J. Discovery of intestinal targeted TGR5 agonists for the
treatment of type 2 diabetes. J. Med. Chem. 2015, 58, 3315−3328.
(40) Ma, S. Y.; Ning, M. M.; Zou, Q. A.; Feng, Y.; Ye, Y. L.; Shen, J.
H.; Leng, Y. OL3, a novel low-absorbed TGR5 agonist with reduced
side effects, lowered blood glucose via dual actions on TGR5
activation and DPP-4 inhibition. Acta Pharmacol. Sin. 2016, 37, 1359.
(41) Filipski, K. J.; Varma, M. V.; El-Kattan, A. F.; Ambler, C. M.;
Ruggeri, R. B.; Goosen, T. C.; Cameron, K. O. Intestinal targeting of
drugs: rational design approaches and challenges. Curr. Top. Med.
Chem. 2013, 13, 776−802.
(42) Budzik, B. W.; Evans, K. A.; Wisnoski, D. D.; Jin, J.; Rivero, R.
A.; Szewczyk, G. R.; Jayawickreme, C.; Moncol, D. L.; Yu, H.
Synthesis and structure-activity relationships of a series of 3-aryl-4-
isoxazolecarboxamides as a new class of TGR5 agonists. Bioorg. Med.
Chem. Lett. 2010, 20, 1363−1367.
(43) Martin, R. E.; Bissantz, C.; Gavelle, O.; Kuratli, C.; Dehmlow,
H.; Richter, H. G.; Obst Sander, U.; Erickson, S. D.; Kim, K.;
Pietranico-Cole, S. L.; Alvarez-Sanchez, R.; Ullmer, C. 2-Phenoxy-
nicotinamides are potent agonists at the bile acid receptor GPBAR1
(TGR5). ChemMedChem 2013, 8, 569−576.
(44) Ito, F.; Heard, N.; Kobayashi, H.; Kanzaki, N. Receptor agonist
(Example 165, CAS# 878292−18−3). JP2006063064, 2006. Available
(20) Armstrong, M. J.; Hull, D.; Guo, K.; Barton, D.; Hazlehurst, J.
M.; Gathercole, L. L.; Nasiri, M.; Yu, J.; Gough, S. C.; Newsome, P.
N.; Tomlinson, J. W. Glucagon-like peptide 1 decreases lipotoxicity in
non-alcoholic steatohepatitis. J. Hepatol. 2016, 64, 399−408.
(21) Ivory, C. P.; Wallace, L. E.; McCafferty, D. M.; Sigalet, D. L.
Interleukin-10-independent anti-inflammatory actions of glucagon-
like peptide 2. Am. J. Physiol Gastrointest Liver Physiol 2008, 295,
G1202−1210.
(22) El-Jamal, N.; Erdual, E.; Neunlist, M.; Koriche, D.; Dubuquoy,
C.; Maggiotto, F.; Chevalier, J.; Berrebi, D.; Dubuquoy, L.; Boulanger,
E.; Cortot, A.; Desreumaux, P. Glugacon-like peptide-2: broad
receptor expression, limited therapeutic effect on intestinal inflam-
mation and novel role in liver regeneration. Am. J. Physiol Gastrointest
Liver Physiol 2014, 307, G274−285.
(23) Schaap, F. G.; Trauner, M.; Jansen, P. L. Bile acid receptors as
targets for drug development. Nat. Rev. Gastroenterol. Hepatol. 2014,
11, 55−67.
(24) Yuan, L.; Bambha, K. Bile acid receptors and nonalcoholic fatty
liver disease. World J. Hepatol 2015, 7, 2811−2818.
(25) Jeppesen, P. B.; Sanguinetti, E. L.; Buchman, A.; Howard, L.;
Scolapio, J. S.; Ziegler, T. R.; Gregory, J.; Tappenden, K. A.; Holst, J.;
Mortensen, P. B. Teduglutide (ALX-0600), a dipeptidyl peptidase IV
resistant glucagon-like peptide 2 analogue, improves intestinal
function in short bowel syndrome patients. Gut 2005, 54, 1224−1231.
(26) Schwartz, L. K.; O’Keefe, S. J.; Fujioka, K.; Gabe, S. M.;
Lamprecht, G.; Pape, U. F.; Li, B.; Youssef, N. N.; Jeppesen, P. B.
Long-term teduglutide for the treatment of patients with intestinal
failure associated with short bowel syndrome. Clin. Transl. Gastro-
enterol. 2016, 7, e142.
(27) Pols, T. W.; Nomura, M.; Harach, T.; Lo Sasso, G.; Oosterveer,
M. H.; Thomas, C.; Rizzo, G.; Gioiello, A.; Adorini, L.; Pellicciari, R.;
Auwerx, J.; Schoonjans, K. TGR5 activation inhibits atherosclerosis by
reducing macrophage inflammation and lipid loading. Cell Metab.
2011, 14, 747−757.
(28) Wang, Y. D.; Chen, W. D.; Yu, D.; Forman, B. M.; Huang, W.
The G-protein-coupled bile acid receptor, Gpbar1 (TGR5),
negatively regulates hepatic inflammatory response through antago-
nizing nuclear factor kappa light-chain enhancer of activated B cells
(NF-kappaB) in mice. Hepatology 2011, 54, 1421−1432.
(29) Yoneno, K.; Hisamatsu, T.; Shimamura, K.; Kamada, N.;
Ichikawa, R.; Kitazume, M. T.; Mori, M.; Uo, M.; Namikawa, Y.;
Matsuoka, K.; Sato, T.; Koganei, K.; Sugita, A.; Kanai, T.; Hibi, T.
TGR5 signalling inhibits the production of pro-inflammatory
cytokines by in vitro differentiated inflammatory and intestinal
macrophages in Crohn’s disease. Immunology 2013, 139, 19−29.
(30) Cipriani, S.; Mencarelli, A.; Chini, M. G.; Distrutti, E.; Renga,
B.; Bifulco, G.; Baldelli, F.; Donini, A.; Fiorucci, S. The bile acid
receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier
and immune response to experimental colitis. PLoS One 2011, 6,
e25637.
(31) Sakanaka, T.; Inoue, T.; Yorifuji, N.; Iguchi, M.; Fujiwara, K.;
Narabayashi, K.; Kakimoto, K.; Nouda, S.; Okada, T.; Kuramoto, T.;
Ishida, K.; Abe, Y.; Takeuchi, T.; Umegaki, E.; Akiba, Y.; Kaunitz, J.
D.; Higuchi, K. The effects of a TGR5 agonist and a dipeptidyl
peptidase IV inhibitor on dextran sulfate sodium-induced colitis in
mice. J. Gastroenterol. Hepatol. 2015, 30 (Suppl1), 60−65.
(32) Hanauer, S. B. Inflammatory bowel disease: epidemiology,
pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006,
12 (Suppl 1), S3−9.
(33) Li, T.; Holmstrom, S. R.; Kir, S.; Umetani, M.; Schmidt, D. R.;
Kliewer, S. A.; Mangelsdorf, D. J. The G protein-coupled bile acid
receptor, TGR5, stimulates gallbladder filling. Mol. Endocrinol. 2011,
25, 1066−1071.
(45) Galia, E.; Nicolaides, E.; Horter, D.; Lobenberg, R.; Reppas, C.;
Dressman, J. B. Evaluation of various dissolution media for predicting
in vivo performance of class I and II drugs. Pharm. Res. 1998, 15,
698−705.
(46) Ritchie, T. J.; Macdonald, S. J. The impact of aromatic ring
count on compound developability–are too many aromatic rings a
liability in drug design? Drug Discovery Today 2009, 14, 1011−1020.
(47) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.
Experimental and computational approaches to estimate solubility and
permeability in drug discovery and development settings. Adv. Drug
Delivery Rev. 2001, 46, 3−26.
(48) Charmot, D. Non-systemic drugs: a critical review. Curr.
Pharm. Des. 2012, 18, 1434−1445.
(34) Keitel, V.; Cupisti, K.; Ullmer, C.; Knoefel, W. T.; Kubitz, R.;
Haussinger, D. The membrane-bound bile acid receptor TGR5 is
localized in the epithelium of human gallbladders. Hepatology 2009,
50, 861−870.
(49) Rais, R.; Acharya, C.; Mackerell, A. D.; Polli, J. E. Structural
determinants for transport across the intestinal bile acid transporter
using C-24 bile acid conjugates. Mol. Pharmaceutics 2010, 7, 2240−
2254.
X
J. Med. Chem. XXXX, XXX, XXX−XXX